HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TG6-10-1

brain-permeant prostaglandin E receptor 2 antagonist; structure in first source

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - TG6-10-1: 7

Experts

1.	Ganesh, Thota: 5 articles (10/2020 - 02/2013)
2.	Dingledine, Raymond: 4 articles (01/2020 - 02/2013)
3.	Jiang, Jianxiong: 3 articles (08/2020 - 02/2013)
4.	Rojas, Asheebo: 3 articles (01/2020 - 06/2015)
5.	Dingledine, Ray: 2 articles (10/2020 - 01/2019)
6.	Yu, Ying: 2 articles (08/2020 - 01/2019)
7.	Caskurlu, Aysegul: 1 article (10/2020)
8.	Jiang, Chunxiang: 1 article (10/2020)
9.	Hao, Jiukuan: 1 article (08/2020)
10.	Hou, Ruida: 1 article (08/2020)

Related Diseases

1.	Neuroinflammatory Diseases 01/01/2020 - "Administration of six doses of the selective EP2 antagonist TG6-10-1 over a 2-3 day period accelerates functional recovery, attenuates hippocampal neurodegeneration, neuroinflammation, gliosis and blood-brain barrier leakage, and prevents long-term cognitive deficits without blocking SE itself or altering acute seizure characteristics. " 10/01/2020 - "Our results show that an EP2 antagonist, TG6-10-1, promotes the recovery of body weight, mitigates neuroinflammation as judged by inflammatory cytokines and microgliosis, prevents the loss of synaptic proteins, and ameliorates depression-like behavior in the sucrose preference test as well as memory loss in the novel object recognition test. "
2.	Memory Disorders (Memory Loss) 10/01/2020 - "Our results show that an EP2 antagonist, TG6-10-1, promotes the recovery of body weight, mitigates neuroinflammation as judged by inflammatory cytokines and microgliosis, prevents the loss of synaptic proteins, and ameliorates depression-like behavior in the sucrose preference test as well as memory loss in the novel object recognition test. "
3.	Body Weight (Weight, Body) 10/01/2020 - "Our results show that an EP2 antagonist, TG6-10-1, promotes the recovery of body weight, mitigates neuroinflammation as judged by inflammatory cytokines and microgliosis, prevents the loss of synaptic proteins, and ameliorates depression-like behavior in the sucrose preference test as well as memory loss in the novel object recognition test. "
4.	Status Epilepticus (Complex Partial Status Epilepticus) 01/01/2019 - "Utilizing a bioavailable and brain-permeant compound, TG6-10-1, we found that pharmacological inhibition of EP2 receptor after a one-hour episode of kainate-induced status epilepticus (SE) in mice reduced seizure-promoted functional deficits, cytokine induction, reactive gliosis, blood-brain barrier impairment, and hippocampal damage. " 06/01/2015 - "Treatment with TG6-10-1 or vehicle did not alter the observed behavioral seizures, however six doses of TG6-10-1 starting 80-150 min after the onset of DFP-induced SE significantly reduced neurodegeneration in the hippocampus, blunted the inflammatory cytokine burst, reduced microglial activation and decreased weight loss in the days after status epilepticus. " 02/26/2013 - "We found that in the mouse pilocarpine model of status epilepticus (SE), systemic administration of TG6-10-1 completely recapitulates the effects of conditional ablation of cyclooxygenase-2 from principal forebrain neurons, namely reduced delayed mortality, accelerated recovery from weight loss, reduced brain inflammation, prevention of blood-brain barrier opening, and neuroprotection in the hippocampus, without modifying seizures acutely. "
5.	Seizures (Absence Seizure) 11/01/2016 - "A single intraperitoneal injection of TG6-10-1 or vehicle 1 h prior to DFP did not alter the development of seizures, the latency to SE or the duration of SE. " 06/01/2015 - "Treatment with TG6-10-1 or vehicle did not alter the observed behavioral seizures, however six doses of TG6-10-1 starting 80-150 min after the onset of DFP-induced SE significantly reduced neurodegeneration in the hippocampus, blunted the inflammatory cytokine burst, reduced microglial activation and decreased weight loss in the days after status epilepticus. " 02/26/2013 - "We found that in the mouse pilocarpine model of status epilepticus (SE), systemic administration of TG6-10-1 completely recapitulates the effects of conditional ablation of cyclooxygenase-2 from principal forebrain neurons, namely reduced delayed mortality, accelerated recovery from weight loss, reduced brain inflammation, prevention of blood-brain barrier opening, and neuroprotection in the hippocampus, without modifying seizures acutely. "

Related Drugs and Biologics

1.	Cytokines
2.	Sucrose (Saccharose)
3.	Proteins (Proteins, Gene)
4.	Isoflurophate (DFP)
5.	Cyclooxygenase 2 (Cyclooxygenase-2)
6.	Pilocarpine (Ocusert)
7.	Kainic Acid (Kainate)

Related Therapies and Procedures

1.	Intraperitoneal Injections